SCHEMBL1037249

SCHEMBL1037249

CCOP(=O)(Cc1cccc(Oc2ccc(Cl)cn2)c1)OCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.41
MAPK1 P28482 1/20 0.41
PPARG P37231 1/20 0.39
CCNT1 O60563 3/20 0.38
CDK9 P50750 3/20 0.38
LIPE Q05469 1/20 0.38
ALDH1A1 P00352 4/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 1/20 0.37
BRCA1 P38398 1/20 0.37
HBB P68871 1/20 0.37
HSD17B10 Q99714 1/20 0.37
P2RX3 P56373 2/20 0.37
HRH3 Q9Y5N1 1/20 0.36
POLB P06746 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
BTK Q06187 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1011533 0.87 MAPK1 (0.42) MAPK1PPARGCCNT1CDK9ALDH1A1
SCHEMBL30903848 0.86 MAPK1 (0.41) MAPK1CCNT1CDK9ALDH1A1MEN1
SCHEMBL27233677 0.86 MAPK1 (0.44) MAPK1PPARGCCNT1CDK9ALDH1A1
SCHEMBL1011032 0.86 MAPK1 (0.41) MAPK1CCNT1CDK9ALDH1A1MEN1
SCHEMBL30677804 0.83 MAPK1 (0.64) FAAHMAPK1LIPEALDH1A1KDM4E
SCHEMBL1009588 0.83 MAPK1 (0.64) FAAHMAPK1LIPEALDH1A1KDM4E
SCHEMBL4058017 0.83 FAAH (0.46) FAAHPPARGLIPEALDH1A1MEN1
SCHEMBL27233661 0.82 CCNT1 (0.39) MAPK1CCNT1CDK9ALDH1A1MEN1
SCHEMBL27094607 0.82 CCNT1 (0.44) CCNT1CDK9
SCHEMBL27234556 0.81 LMNA (0.42) MAPK1CCNT1CDK9ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11998538-B2 Piperidine urea derivatives as soluble epoxide hydrolase inhibitors NEUROPN THERAPEUTICS (US) 2024-06-04 US disclosed
US-11998538-B2 Piperidine urea derivatives as soluble epoxide hydrolase inhibitors NEUROPN THERAPEUTICS (US) 2024-06-04 US disclosed
EP-2276736-A1 4- [3- (ARYLOXY) BENZYLIDEN]-3-METHYL PIPERIDINE 5-MEMBERED ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS Pfizer Inc. (US) 2011-01-26 EP disclosed
EP-2276737-A1 4- [3- (ARYLOXY) BENZYLIDENE]-3-METHYL PIPERIDINE ARYL CARBOXAMIDE COMPOUNDS USEFUL AS FAAH INHIBITORS Pfizer Inc. (US) 2011-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11998538-B2 Piperidine urea derivatives as soluble epoxide hydrolase inhibitors EPHX1, EPHX2, HPGDS FAAH 8/4885MAPK1 3609/4885PPARG 1332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.